Spinal CB2 Agonist Findings in Rats Depended on an Intrathecal Route

An intervention delivered into the spinal-fluid space cannot be treated as equivalent to oral or smoked cannabis. A rat nerve-injury study found effects of intrathecal JWH015 on hypersensitivity and immune-related markers.

The experiment located receptors and measured behavior

Researchers examined CB2 receptor localization after spinal nerve transection and assessed mechanical withdrawal thresholds. They identified receptors on microglial and perivascular cells and measured changes in selected spinal immune markers.

The antagonist comparison supported receptor involvement

JWH015's reported effects were prevented by a CB2 antagonist but not by the tested CB1 antagonist. Repeated intrathecal treatment did not produce antinociceptive tolerance under the study conditions, and selected behavioral side effects were not observed.

Route and endpoint constrain translation

Those findings concern a specific compound delivered close to the spinal target. They do not establish that consuming cannabis reaches the same target exposure or produces the same benefit. A mechanical withdrawal threshold is also not a patient-reported pain outcome.

The absence of measured side effects should remain tied to the assessments and regimen used. It is not proof of general human safety. The study supports a spinal receptor and immune-modulation hypothesis while leaving clinical effectiveness, appropriate administration and broader adverse effects as separate questions.

Related: interpreting cannabis tolerance claims.

Research cited

Romero-Sandoval A; Nutile-McMenemy N; DeLeo JA. Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury. Anesthesiology (2008). doi:10.1097/ALN.0b013e318167af74. Findings discussed from the study abstract.